Category Press Releases

Revolution Medicines Reports Initial Data on RMC-9805 Monotherapy in Advanced Pancreatic Cancer

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company specializing in targeted therapies for RAS-driven cancers, has announced promising early data on RMC-9805, a selective inhibitor for the RAS(ON) G12D mutation. The preliminary safety and antitumor results for RMC-9805 were…

Read MoreRevolution Medicines Reports Initial Data on RMC-9805 Monotherapy in Advanced Pancreatic Cancer

GenSight Biologics Provides Business Update and Cash Position as of September 30, 2024

GenSight Biologics Reports €3.4 Million Cash Position as of September 30, 2024, and Business Update GenSight Biologics (“GenSight” or the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing innovative gene therapies for retinal neurodegenerative diseases…

Read MoreGenSight Biologics Provides Business Update and Cash Position as of September 30, 2024

Merz Therapeutics and World Stroke Organization Launch Initiative to Enhance Stroke Treatment in Africa

Launch of Access to Health Initiative Announced at World Stroke Congress The World Stroke Organization (WSO) President, Dr. Sheila Martins, officially launched the Access to Health initiative at the annual World Stroke Congress in Abu Dhabi. This collaboration with Merz…

Read MoreMerz Therapeutics and World Stroke Organization Launch Initiative to Enhance Stroke Treatment in Africa

Median Technologies Releases Q3 2024 Operational and Financial Update

eyonis™ LCS Achieves Key Milestones in REALITY Study; Upcoming Webcast Scheduled Key Highlights: Operational and Financial Overview:Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announced that its Board of Directors approved the consolidated IFRS financial statements for H1 2024 on October 23,…

Read MoreMedian Technologies Releases Q3 2024 Operational and Financial Update

Groundbreaking AI-Powered Solutions for Consumer-Controlled Health Information Management

YourHealth Launches YourHealth Life: A Revolutionary Subscription-Based Health Management Tool YourHealth, a leader in consumer-controlled health applications, is thrilled to announce the launch of YourHealth Life, an innovative suite of subscription-based features designed to significantly enhance the consumer health management…

Read MoreGroundbreaking AI-Powered Solutions for Consumer-Controlled Health Information Management

Valor Compounding Pharmacy Seeks New Partnerships with Medical Practices and Hospital Systems

Valor Compounding Pharmacy Invites New Partnerships with Medical Practices and Hospital Systems Valor Compounding Pharmacy, a prominent provider of compounded medications, is excited to announce its initiative to form new partnerships with medical practices and health systems. This effort aims…

Read MoreValor Compounding Pharmacy Seeks New Partnerships with Medical Practices and Hospital Systems

MedGenome Names Felix Olale, M.D., Ph.D., as CEO and Jennifer Rose as CCO to Drive U.S. Expansion

New Leadership Team Set to Drive Growth and Innovation in Precision Medicine MedGenome, a leader in multiomics and precision medicine, has announced the appointment of Felix Olale, M.D., Ph.D., as President and Chief Executive Officer, and Jennifer Rose as Executive…

Read MoreMedGenome Names Felix Olale, M.D., Ph.D., as CEO and Jennifer Rose as CCO to Drive U.S. Expansion

NImmune Biopharma Secures Asian Rights to Develop and Commercialize Omilancor

NImmune Biopharma, a late-clinical-stage biopharmaceutical company specializing in precision inflammation and immunology (I&I) therapeutics, has announced the acquisition of development and commercialization rights to omilancor across several Asian markets, including China, Hong Kong, Taiwan, South Korea, and others. This transaction…

Read MoreNImmune Biopharma Secures Asian Rights to Develop and Commercialize Omilancor

Nucleus RadioPharma Boosts Radiopharmaceutical R&D and Production to Address U.S. Supply Chain Challenges

Nucleus RadioPharma announced the development of two new facilities, totaling over 100,000 square feet, in Mesa, Arizona, and Spring House, Pennsylvania. These state-of-the-art sites will integrate research, development, and commercial production under one roof, providing significant time and scale advantages…

Read MoreNucleus RadioPharma Boosts Radiopharmaceutical R&D and Production to Address U.S. Supply Chain Challenges